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Abstract
Background. Th e mortality burden of cancer continues to increase in developing countries, most likely 
because of a late stage at diagnosis. Identify the terminal stage is important in patients with advanced cancer 
because no longer aggressive therapy in patients with terminal cancer. Palliative prognostic score (PaP score) 
is a scoring system to predict the probability of survival within 30 days in patients with advanced cancer. 
PaP score divided to the heterogeneous patient sample into three iso-prognostic groups related to the chance 
of 30-days survival. Group A, score: 0 to 5.5 (the probability of survival within 30 days > 70%); Group 
B, score: 6-11 (the probability of survival in 30 days 30-70%) and group C, the score: 11.5 to 17.5 (the 
probability of survival in 30 days <30%).
Aims. Th e aim of this study were to validate and to evaluate the prognostic accuracy of the palliative 
prognostic (PaP score) to predict 30-days survival in patients with metastatic cancers in Dr. Sardjito   General 
Hospital Yogyakarta.
Methods. Th e design of this prognostic study was cohort, included patients with metastatic cancers were 
visited in Tulip Hematology and Medical Oncology Clinic, inpatient and outpatient care in the Dr. Sardjito 
General hospital during May 2015 until May 2016. Th e PaP score calculated in 159 consecutive patients 
with metastatic cancers. Th e positive predictive value of the PaP score was evaluated and survival analysis 
was performed to compare the survival of the three prognostic groups.
Results. PaP score tested on 159 subjects with overall median survival was 90 days, 76 subjects categorized 
into group A, 22 subjects into group B and 61 patients into group C. Th e 30-day survival probability was 
98.7% for group A (median survival could not be assessed), 63.6 % probability of 30-day survival for group 
B with median survival was 35 days and for group C with 3.3% probability of 30-day and median survival 
was 6 days. Th ese survival diff erences were highly signifi cant (log-rank test of trends, X2=203.97; P<0.0001). 
Positive predictive value of PaP score in predicting 30-day mortality was 96.7% with an accuracy of PaP 
score was 93.1%.
Conclusion. PaP score was a valid test tool in determining prognosis in patients with metastatic cancers 
with high accuracy and precision in predicting 30-days survival.
Keywords.  PaP score,  validation,  survival,  prognostic,  metastatic cancers.
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Introduction
According from the International Agency 
for Research on Cancer (IARC), there were 14.1 
million new cancer cases in 2012 worldwide 
and total cancer deaths in 2012 were 8.2 
million, of which 56.8 % cases and 64.9 % 
deaths occurred in eco nomically developing 
countries. By 2025, the global burden expected 
to grow.1
Although the total incidence rate in 
developed countries is almost the same as 
developing countries, but the life expectancy 
of cancer in developing countries is worse, 
because in developing countries many people 
with cancer came at an advanced stage.2,3 
Identify the terminal stage is important in 
patients with terminal cancer because in 
patients with terminal cancer, the therapy is 
no longer aggressive, because it will reduce the 
quality of life and increase the cost of medical 
services. Estimating prognosis is one of the 
most diffi  cult tasks the oncologist encounters, 
particularly for patients with advanced stage4. 
In order to assist the clinician in estimating 
prognosis, several groups attempted to identify 
specifi c survival predictors and incorporate 
these variables into a prognostic score.5 
Palliative prognostic score (PAP score) was 
developed in a prospective, multicenter study of 
519 patients with advanced solid tumor in Italia 
who were no longer receiving chemotherapy. 
PAP score combine Karnofksy performance 
status, clinical symptoms (anorexia and 
dyspnea), hematologic parameters (leukocytes 
and lymphocytes) and clinical predictions 
Abstrak
Latar belakang. Adanya peningkatan insidensi dan kematian akibat kanker di negara berkembang karena 
banyaknya penderita kanker yang datang ke pelayanan kesehatan sudah dengan stadium lanjut. Identifi kasi 
kelompok stadium terminal penting dilakukan karena penderita kanker stadium terminal tidak lagi diberikan 
terapi agresif. Palliative prognostic score (PaP score) merupakan suatu sistem penilaian untuk membantu klinisi 
dalam memprediksi probabilitas kesintasan dalam 30 hari pada penderita kanker stadium lanjut. PaP score 
terbagi dalam 3 kategori, yaitu : Grup A, skor : 0-5,5 (probabilitas kesintasan dalam 30 hari >70%); grup B, 
skor : 6-11 (probabilitas kesintasan dalam 30 hari 30-70%) dan grup C, skor :11,5-17,5 (probabilitas kesintasan 
dalam 30 hari <30%).
Tujuan. Penelitian ini bertujuan untuk melakukan uji validasi dan evaluasi akurasi prognostik PaP score dalam 
memprediksi kesintasan dalam 30 hari pada penderita kanker stadium metastasis di RSUP Dr Sardjito Yogyakarta. 
Metode. Desain penelitian prognostik ini menggunakan desain kohort, mengikutkan pasien-pasien penderita 
kanker stadium metastasis di polikllinik Tulip, instalasi rawat inap dan rawat jalan di RSUP Dr Sardjito selama 
bulan Mei 2015-Mei 2016. Sebanyak 159 pasien yang ikut dalam penelitian ini dilakukan penilaian PaP score, 
kemudian subyek penelitian diikuti selama 30 hari setelah penilaian. Evaluasi nilai duga positif dan analisis 
kesintasan dilakukan untuk membandingkan kesintasan diantara ketiga grup PaP.
Hasil Penelitian. Seratus tujuh puluh sembilan subyek dianalisis dengan median kesintasan 90 hari, 76 pasien 
dikategorikan ke dalam grup A, 22 pasien masuk ke dalam grup B dan 61 pasien ke dalam grup C. Probabilitas 
kesintasan dalam 30 hari untuk grup A 98,7 %, grup B 63,6 % dan grup C 3,3 %. Median kesintasan grup B 
35 hari dan grup C 6 hari, sedangkan pada grup A median kesintasan belum dapat dinilai. Perbedaan kesintasan 
pada ketiga grup menunjukkan hasil yang bermakna (X2=203,97; P<0,0001). Nilai duga positif PaP score 
dalam memprediksi kematian dalam 30 hari sebesar 96,7 % dengan akurasi 93,1 %.
Kesimpulan. PaP score merupakan alat uji yang valid dalam menentukan prognosis pada pasien kanker stadium 
metastasis dengan akurasi dan presisi yang tinggi dalam memprediksi kesintasan dalam 30 hari
Kata kunci: : PaP score, validasi, kesintasan, prognosis, kanker stadium metastasis. 
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survival. Patients divided into 3 groups based 
on the probability of surviving in 30 days. 
Group A with a good prognosis, score: 0 to 
5.5 (the probability of survival within 30 days> 
70%); Group B with intermediate prognosis, 
score: 6-11 (the probability of survival within 
30 days amounted to 30-70%) and group C 
with a poor prognosis, score: 11.5 to 17.5 (the 
probability of survival in 30 days <30%).6
Method
Th e design of this prognostic study was 
cohort. Th e aim of this study was to validate 
and to evaluate the prognostic accuracy of 
the PaP score in predicting 30-days survival 
in patients with metastatic cancer. Th e study 
was conducted in Tulip clinic, inpatient and 
outpatient care in the Dr. Sardjito hospital 
during May 2015 to May 2016. Th e subjects 
were all patients with metastatic cancers in 
Tulip clinic, inpatient and outpatient care in 
the Dr. Sardjito hospital, who met the inclusion 
and exclusion criteria. Th e PaP score calculated 
in all patients, patients followed for 30 days 
after the assessment. Inclusion criteria for this 
study was aged above 18 years with cancer 
diagnosis of metastatic stage proved with the 
histopathologic examination and evidence 
of any distant metastases, either through 
histopathological and radioimaging. Exclusion 
criteria were patients with hematologic cancer. 
Th e patient were willing to join the study and 
signed an agreement contract.
Statistic Analysis
Th e Kaplan-Meier method and log-rank 
test used to compare the survival distribution 
of patients in the three PaP score groups. Th e 
positive predictive value (PPV) and negative 
predictive value (NPV) used to describe 
prognostic accuracy of the PaP score in 
predicting 30 days-survival in patients with 
metastatic cancers.
Table 1. Baseline characteristics
Characteristic Number (percentage) 
Age (year) 
Median 53
Range 19-81
Age < 60 year –number (%) 112 (70.4 %)
Sex
Male 56 (35.2 %)
Female 103 (64.8 %)
Primary cancer site
Breast  59 (37.1 %)
Colorectal 33 (20.8 %)
Lung 18 (11.3 %)
Head and neck 17 (10.7 %)
Liver, biliary tract and upper GI 10 (6.3 %)
Lain-lain 22 (13.8 %)
Metastatic location
Lung 68 (42.8 %)
Liver 41 (25.8 %)
Bone 23 (14.5 %)
Brain 14 (8.8 %)
Others 13 (8.2 %)
Current treatment
Active therapy 95 (60.4 %)
Chemotherapy 76 (48.4 %)
Radiotherapy   4 (  2.5 %)
Hormonal 15 (  9.4 %)
Nil 64 (39.6 %)
Line of chemotherapy
One 74
Two  38
Th ree 5
Comorbidity
Diabetes 15
Hypertension 12
Heart failure 5
Renal failure 1
Asthma 1
Stroke 1
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Results
Th ere were 159 subjects included in the 
PaP score study. The baseline characteristics 
of patient listed in Table 1. Th e 159 subjects 
included 103 female (64.8 %) and the median 
age was 53 years (range, 19 to 81 years). Th e most 
frequent primary cancer sites were as follows: 
breast (37.1 %), colorectal (20.8 %), lung (11.3 
%), and head and neck (10.7 %). The most 
frequent metastases site was lung (42.8%), liver 
(25.8%), bone (14.5% ) and the brain (8.9%). 
At the time of study enrollment, 95 patients had 
received active therapy and 64 patients without 
therapy. Diabetes and hypertension were the 
most common comorbidity. Th e prevalence of 
abnormalities contributing to the PAP scores are 
shown in Table 2.
Table 2. PaP score items in the participants
Item Number (percentage)
Symptoms 
Anorexia 98 (61.6 %)
Dyspnea 92 (57.9 %)
Karnofsky performance score (KPS)
>60 59 (37.1 %)
50-60 28 (17.6 %)
30-40 28 (17.6 %)
10-20 44 (27.7 %)
Clinical estimate of survival, weeks
>12 weeks 78(49.1 %)
11-12 weeks 2 (1.3 %)
7-10 weeks 11 (6.9 %)
5-6 weeks 13 (8.2 %)
3-4 weeks 37 (23.3 %)
1-2 weeks 18 (11.3 %)
Hematologic parameters
Total WBC count, x 103/L
≤ 8.5 74 (46.5 %)
8.6-11 15 (9.5 %)
> 11 70  (44 %)
Lymphocyte  percentage (%)
≥20 54 (34 %)
12-19.9 25 (15.7 %)
< 12 80 (50.3 %)
Most subjects complained of anorexia 
(61.6 %) and dyspnea (57.9 %). Th e median 
KPS was 60 and 27.7 % patients had KPS 
score of less than 20. WBC and lymphocyte 
percentage abnormalities were common. Most 
patients showed abnormal laboratory results, 
mild leukocytosis (> 8 x 103 / L) was found 
53.5% and lymphopenia (<12%) of 50.3%.
Th e median WBC count was 9.76 x 103/L and 
the median lymphocyte count as a percentage 
of total WBC count was 12.3%.
Th e median survival was 90 days (range: 
9-170). To validate the PaP score method, 
the scoring procedures applied. Th is resulted 
in 76 subjects being categorized into the best 
prognostic group, group A (PaP score 0-5.5), 
22 subjects into the intermediate group, group 
B (PaP score 6-11) and 61 subjects into the 
worst prognostic group, group C (PaP score 
11.5-17.5). Th e Kaplan-Meier survival curves 
for the 3 groups PaP are shown in Figure 1. Th e 
median survival was 35 days (95 % CI : 21-49) 
for group B, 6 days (95 % CI : 5-7) for group 
C and for group A median survival cannot be 
assessed yet because <50% of the study subjects 
from group A were died. Diff erences survival 
among groups were highly signifi cant (X2= 
203.97, p<0.0001).
Evaluation  given after 30 days of PaP, 75 
out of 76 subjects in group A were survived, in 
group B with 14 of 22 patients survived and 
in group C were 2 of 61 patients survived.Th e 
30-day survival probability for each group was 
98.7 % for group A, 63.6 % for group B and 
3.3 % for group C.
The positive predictive value as the 
amount of patients with a poor prognosis 
(group C) who died within 30 days of the 
PaP score reaches 96.7 % (59 out of 61). Th e 
negative predictive value as the amount of 
patients with a good prognosis (group A& 
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B) who survived within 30 days of the PaP 
score reaches 90.8 % (89 out of 98). The 
accuracy of PaP score in predicting prognosis 
in subjects with metastatic cancers was 93.1 
%. PaP score analysis based on the current 
treatment of the subjects , from 159 subjects 
there were 95 subjects received active treatment 
(chemotherapy / radiotherapy / hormonal 
therapy) and 64 subjects did not received active 
therapy. Th e division of each group can be seen 
in Table 4.
In subjects with active treatment, there 
were 15 (15.8%) subjects died within 30 
days after an assessment of PaP scores and 
in patients without active treatment were 53 
(82.8%) subjects died within 30 days. Of the 
total 98 subjects with PaP score of group A and 
B, 15 (15%) subjects without getting active 
treatment and 83 (85%) subjects were on active 
therapy. In the group of subjects without active 
treatment, fi ve (33.3%) subjects  died within 
30 days, whereas subjects with active treatment 
groups were obtained 4 (4.8%) subjects died 
within 30 days. Test of survival between 
patients who received active treatment and not 
getting active treatment with the log-rank test 
showed a signifi cant diff erence (X2 = 11.010; 
p = 0.0001).
Figure 2. Kaplan-Meier survival curve for 
group A & B
Figure 2 showed the curve of Kaplan-
Meier overall survival in subjects with PaP 
score of group A and B based on the status of 
therapy. Overall survival curves Kaplan-Meier 
Figure 1. Kaplan-Meier survival curve of three 
groups PaP  
Table 3. Th e 30-day probability and estimated 
median survival for the three PaP groups 
(n=159)
PaP 
group
No. of  
patients in 
group
No. alive at 
30 days 
(percentage)
Estimated 
median 
survival (days)
Grup A 76 75 (98.7%) -
Grup B 22 14 (63.3%) 35
Grup C 61 2 (3.3%) 6
Table 4. PaP score analysis based on current 
treatment
PaP
group
No. of patients 
in group
No. dead at 30 
days (percentage)
Without 
treatment
A 7 0 (0 %)
B 8 5 (62.5 %)
C 49 48 (97.9 %)
Total 64 53 (82.8 %)
active 
treatment 
A 69 1 (1.45 %)
B 14 3 (21.4 %)
C 12 11 (91.7 %)
Total 95 15 (15.8 %)
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shows signifi cant diff erences between group A 
and B subjects who received active treatment 
or no treatment. In the group of subjects who 
did not receive therapy, the median survival of 
60 days (95% CI :  1-135) and in subjects who 
received active treatment the median survival 
could not be assessed yet because <50% of the 
study subjects from group A died.
In the group of subjects with the worst 
prognosis or C group there were 49 (80.3%) 
subjects did not receive active therapy and 12 
(19.7%) subjects still receive active therapy. 
48 (97.9%) subjects without active treatment 
died within 30 days after an assessment of PaP 
scores and in subjects with active treatment 
group there were 11 (91.7%) subjects died 
within 30 days. In the group of subjects 
receiving active therapy, the median survival 
of 7 days (95% CI: 1-20) and in subjects who 
did not receive active treatment the median 
survival of 6 days (95% CI: 4-7). Diff erences 
survival among groups using the log-rank test 
test showed a non-signifi cant (X2= 2.949; p= 
0.08). Overall survival curves Kaplan-Meier at 
PaP score C group based therapy status can be 
seen in Figure 3.
Figure 3. Kaplan-Meier survival curve for group C 
Discussion
In this study, the 30-day survival 
probability for group A was 98.7 %, group 
B 63.6 % and group C 3.3 %. The PaP 
score successfully divided patients into three 
groups based on 30-day survival probability. 
There were 30-day survival probability for 
each group; 98.7 % for group A, 63.6 %, for 
group B and 3.3 % for group C. Th e results 
correspond to the results of study conducted by 
Pirovano. Patients were divided into 3 groups 
based on the probability of surviving in 30 
days. Group A with a good prognosis, score: 
0 to 5.5 (the probability of survival within 
30 days> 70%). Group B with intermediate 
prognosis, score: 6-11 (the probability of 
survival within 30 days amounted to 30-70%) 
and group C with a poor prognosis, score: 11.5 
to 17.5 (the probability of survival in 30 days 
<30%). Th e median survival was 35 days (95 
% CI : 21-49) for group B, 6 days (95 % CI : 
5-7) for group C and for group A, the median 
survival cannot be assessed, because there is 
no 50% of the subjects in group A who died. 
Diff erences survival among groups were highly 
signifi cant (X2= 203.97, p<0.0001)
Maltoni et al8, conducted a validation of 
the PAP score in a population almost equal to 
the population used in the study conducted 
by Pirovano. Subjects were 451 patients with 
advanced cancer of 14 palliative care centers in 
Italy. Th e results showed group A, the median 
survival was 76 days and the probability of 
survival in 30 days was 86.6%, while in Group 
B 32 days with a probability of 51.6% and 
in group C of 14 days with a probability of 
16.9%7.
A similar study conducted by Glare 
and colleagues, validation of PaP score in 
100 patients with advanced cancer who were 
Acta Interna The Journal of  Internal Medicine,  Volume 9, Number 1, June 2019: 15-23
21 
hospitalized in the oncology ward in a teaching 
hospital in Australia. Th e results showed the 
probability of 30-day survival in group A was 
97%, group B was 59 % and group C was 25%, 
with a median survival of each group was 17 
weeks for the group A, 7 weeks  for group B 
and group C <1 weeks.5 Several studies on the 
validation of PAP score can be seen in Table 5.
In this study, the PAP score has a high 
positive predictive value or precision in the 
amount of 96.7% and a negative predictive 
value of 90.8%. Th e accuracy of PAP score in 
predicting the prognosis of patients within 30 
days amounted to 93.1%. Th e results of this 
study indicated that PAP score can be used as 
a tool to help clinicians determine prognosis 
in patients with metastatic stage cancer with a 
high level of accuracy and precision.
Maltoni et al (2012) compared four 
different prognostic scores in palliative 
care cancer populations in Italia. The PaP 
score showed highest accuracy among other 
prognostic score. Th e accuracy  at 30 days of 
follow-up of PaP score was 88 %, 79.6 % for 
D-PaP score, 75.6 % for CPS, 72.3 for PPI 
(palliative prognostic index) and <50 % for 
PPS (palliative performance scale).8
In patients with good prognosis (PAP 
score group A & B), patients who did not 
receive active therapy, the median survival 
was 60 days (95% CI : 1-135) and in patients 
who received active therapy the median 
survival could not be assessed (>240 days). 
Th e comparison among these 2 groups were 
performed with the log-rank test (X2= 11.010; 
p < 0.0001), whereas in the patients with 
worst prognosis (PaP score group C), the 
median survival in patients who received active 
treatment was 7 days (95% CI : 1-20) and in 
patients who did not receive active treatment 
the median survival was 6 days (95% CI : 
4-7). Th e comparison among these 2 groups 
were performed with the log-rank test (X2 = 
2.94; p < 0.08), Active cancer therapy given to 
a patient with months of life expectancy (PaP 
score gorup A&B) may result in symptom 
control and improved survival, whereas in 
patients with a poor prognosis (PaP score group 
C), anti-cancer therapy should be considered 
carefully, because it is not proven improve 
survival. Th e implication of this study is in 
patients with PAP score group C no longer be 
given aggressive therapy, because it will reduce 
the quality of life of patients and increase the 
cost of medical services.
Many patients with terminal cancer are 
off ered chemotherapy in order to improve their 
quality of life and or even be able to prolong 
survival Prigerson and colleagues conducted 
a cohort longitudinal study in 661 patients 
with late-stage cancers, 312 patients received 
at least one regimen of chemotherapy followed 
prospectively until their death. In patients with 
poor performance status (ECOG 3), the use of 
chemotherapy did not improve quality of life.9
ASCO guidelines recommend against the 
use of chemotherapy in solid tumor patients 
who have not benefi ted from prior treatment 
and who have an Eastern Cooperative Oncology 
Group (ECOG)7 performance status score of 
Table 5. PaP score validation 
Patient background  Median survival 30-day survival probability  
Maltoni et al Cancer (n=451) A= 76 days; B= 32 days; C= 14 days A= 86.6%; B= 51.6 %; C=16.9 %
Glare et al Cancer (n=100) A=17 weeks; B=7 weeks; C= <1 week A= 97%;  B= 59%; C= 25 %
Numico  et al Cancer (n=208) Not available A= 92%; B= 48%; C= 22%
Sonoda et al Cancer (n=187) A= 94 days; B=38 days; C= 14 days A= 88.1 %; B= 55.2 %; C= 5%
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3 or more. Palliative chemotherapy given to 
patients with advanced solid tumor and poor 
general status (ECOG 3-4) with short life 
expectancy provided no benefi t for survival. 
As a result, physician may be over-treating 
these patients and contributing to poor-quality 
care.10
Palliative chemotherapy will give side 
effects such as nausea, vomiting, hair loss, 
diarrhea, bone marrow suppression and 
other side eff ects. Chemotherapy produces 
adverse eff ects, precipitates hospitalization and 
emergency department visits, precludes entry 
into most hospices, and may require additional 
supportive care with erythropoietin-like 
drugs and colony-stimulating factors that are 
expensive and contribute little to the patient’s 
overall quality of life.11
Th e use of chemotherapy in terminally ill 
cancer patients in the last months of life was 
associated with an increased risk of underwent 
cardiopulmonary resusitation, mechanical 
ventilation or both and of being referred 
to a hospice late, both of which have been 
associated with worse quality of life for patients 
at the end of life, and higher costs. Th e use of 
palliative chemotherapy was also associated 
with increased risk of dying in an intensive care 
unit a decreased likelihood of dying at home, 
and a lower likelihood that patients died in 
their preferred place.12
Conclusion
Pap test score was a valid tool in 
determining prognosis in patients with 
metastatic cancers. Th e PaP score successfully 
divided patients into three groups based on 30-
day survival probability. Th e 30-day survival 
probability for each group was 98.7 % for 
group A, 63.6 % for group B and 3.3 % for 
group C. PAP score can be used as a tool to 
help clinicians determine prognosis in patients 
with metastatic stage cancer with a high level 
of accuracy and precision.
In the group of patients with a good 
prognosis, active cancer therapy will improve 
survival, whereas in patients with a poor 
prognosis suggested to be given best supportive 
care (BSC) instead of anti-cancer therapy.
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